Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Making Bright Ideas Work: The Trade Group Looking Out for the MedTech Community

Perhaps no state is more renowned for medicine than Massachusetts. The Commonwealth is host to leading hospitals, medical centers, and medical device companies that are maturing next generation technologies. But medtech enterprises large and small need representatives to ensure that innovations in the space can thrive. That’s where Brian Johnson comes in. He is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Perhaps no state is more renowned for medicine than Massachusetts. The Commonwealth is host to leading hospitals, medical centers, and medical device companies that are maturing next generation technologies. But medtech enterprises large and small need representatives to ensure that innovations in the space can thrive.

That’s where Brian Johnson comes in. He is President of the Massachusetts Medical Device Industry Council (MassMEDIC) and on this week’s episode of Making Bright Ideas Work, a Sunrise Labs podcast, he shared insights into his advocacy work.

“We help maintain a healthy environment for medical device innovators,” Johnson said. Medicine is a highly regulated industry so his trade group works with government partners to streamline processes and ensure a healthy ecosystem that fosters innovation.

Whether its pushing for the repeal of the medical device tax or staying atop of Brexit and its complications for medical device companies, MassMEDIC is there looking out for its members and the medtech community as a whole.

“Massachusetts continues to be a robust environment in this space,” he contended, and cited Sunrise Labs as one of the leaders pushing medtech forward. He also works with a number of startups disrupting the industry, and advises that novice CEOs should focus less energy on raising money and more on their plan to go from zero to commercialization.

“You need to think about the entire lifespan of this company as a founder,” Johnson said.

As a former company founder himself, Brian feels passionately about helping other founders. It’s why he’s become a personal champion of MassMEDIC IGNITE, which provides the medtech startup community with training, mentorship, and networking.

“I really love medtech,” Johnson confessed, and said that the innovations advanced by medical device companies are on par with those of the space program.

He is proud and amazed at the medical advances that come out of the Commonwealth. The first surgery with anesthesia was done in Massachusetts and now leading hospitals in the state are performing surgeries using advanced robotics or remote surgeons.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512